Get the Stockscreener App
1.71
8.92%
0.14
After Hours:
1.70
-0.01
-0.58%
Lexicon Pharmaceuticals Inc stock is traded at $1.71, with a volume of 2.47M.
It is up +8.92% in the last 24 hours and up +39.02% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.57
Open:
$1.57
24h Volume:
2.47M
Relative Volume:
1.20
Market Cap:
$621.41M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-2.1375
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
+30.53%
1M Performance:
+39.02%
6M Performance:
+55.45%
1Y Performance:
+78.68%
1-Day Range:
$1.5501
$1.71
1-Week Range:
$1.33
$1.83
52-Week Range:
$0.2836
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.71 | 570.54M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
LIVE: Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - Chartmill
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary - Yahoo Finance
Downgrade Watch: How does Lexicon Pharmaceuticals Inc compare to its peersJuly 2025 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
Lexicon rebounds on FDA nod for phase III non-opioid pain drug trial - BioWorld MedTech
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward - Seeking Alpha
Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week HighHere's Why - MarketBeat
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st
Lexicon Pharmaceuticals (NASDAQ:LXRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Lexicon Pharmaceuticals Boosts Outlook with Strategic Moves - StocksToTrade
Lexicon Pharmaceuticals (LXRX) Soars on Positive FDA Meeting Out - GuruFocus
Lexicon Pharma rises on FDA views on pain drug (LXRX:NASDAQ) - Seeking Alpha
Lexicon (LXRX) Receives FDA Green Light for Phase 3 Trials on Pi - GuruFocus
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain - manilatimes.net
Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Development for Diabetic Peripheral Neuropathic Pain After FDA Meeting - Quiver Quantitative
Lexicon Pharmaceuticals announces successful end-of-phase 2 meeting with FDA for pilavapadin in the treatment of diabetic peripheral neuropathic pain - marketscreener.com
Lexicon Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Pilavapadin In The Treatment Of Diabetic Peripheral Neuropathic Pain - TradingView
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - Sahm
Is Lexicon Pharmaceuticals Inc. stock a bargain at current levelsQuarterly Profit Report & Free Community Consensus Stock Picks - bollywoodhelpline.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) delivers shareholders notable 99% return over 1 year, surging 17% in the last week alone - simplywall.st
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.2% HigherTime to Buy? - MarketBeat
Lexicon flags $10 mln Novo Nordisk milestone and 2026 NDA plans - MSN
Aug PreEarnings: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsQuarterly Market Summary & Expert Approved Momentum Trade Ideas - Bộ Nội Vụ
Published on: 2026-01-13 21:48:56 - Bộ Nội Vụ
Lexicon Pharmaceuticals Publishes Relief is Possible, Ensuring Access to Effective Treatments for Chronic Pain - marketscreener.com
Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference - marketscreener.com
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Experimental heart, diabetes and pain drugs move ahead at Lexicon - Stock Titan
Published on: 2026-01-10 20:09:17 - ulpravda.ru
Lexicon Pharmaceuticals Releases White Paper on Addressing Chronic Pain with Non-Opioid Treatments Following Stakeholder Roundtable - Quiver Quantitative
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Will Lexicon Pharmaceuticals Inc. stock maintain growth storyAnalyst Downgrade & Fast Gain Stock Tips - Улправда
Making Medical Innovation Matter To Patients With Simplified Trial Design - Clinical Leader
Is Lexicon Pharmaceuticals Inc. stock cheap at current valuationTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Market Rankings: Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Performance Recap & Scalable Portfolio Growth Ideas - ulpravda.ru
Is Lexicon Pharmaceuticals Inc. stock resilient to inflationJuly 2025 PostEarnings & Real-Time Buy Signal Notifications - Улправда
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastInstitutional Buying Trends & Calculate Profit Targets With AI Accuracy - earlytimes.in
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Update: Will Lexicon Pharmaceuticals Inc stock outperform Dow Jones index2025 Big Picture & Low Drawdown Trading Strategies - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Is Using Debt Safely - 富途牛牛
Profit Recap: Can Lexicon Pharmaceuticals Inc stock continue upward trendRisk Management & Free Daily Entry Point Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Lexicon Pharmaceuticals accelerates partnerships with patients on innovative therapies - Traders Union
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):